检索结果-南通市图书馆

在线全文

学校读者我要写书评

暂无评论

暴发型肝豆状核变性的治疗及预后分析

中南大学学报（医学版） 2011年第11期36卷 1111-1114页

作者：田沂龚国忠杨旭中南大学湘雅二医院肝病研究中心长沙410011

目的:了解暴发型肝豆状核变性(FWD)的有效治疗方法及影响预后的因素。方法:回顾性分析13例FWD患者。观察采用激素、二巯基丙磺酸钠驱铜、血浆置换联合治疗FWD患者的疗效;对比存活组与死亡组临床特点、生化资料与治疗的差异。结果:13例FW... 详细信息

目的:了解暴发型肝豆状核变性(FWD)的有效治疗方法及影响预后的因素。方法:回顾性分析13例FWD患者。观察采用激素、二巯基丙磺酸钠驱铜、血浆置换联合治疗FWD患者的疗效;对比存活组与死亡组临床特点、生化资料与治疗的差异。结果:13例FWD患者均有重度黄疸,合并重度溶血性贫血7例,自发性腹膜炎5例,肝性脑病8例;凝血酶原活动度(PTA)小于30%者5例。13例患者中采用驱铜联合血浆置换治疗及短期使用激素者7例,存活6例,1例合并自发性腹膜炎且PTA小于30%者死亡;另6例死亡患者中4例合并自发性腹膜炎,4例PTA小于30%。结论:肝衰竭程度及合并感染是决定FWD患者预后的重要因素;采用激素、驱铜、血浆置换是治疗早中期暴发型肝豆状核变性的有效方法之一。

关键词：暴发型肝豆状核变性二巯基丙磺酸钠驱铜血浆置换

96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients

在线全文

学校读者我要写书评

暂无评论

Journal of Clinical and Translational Hepatology 2023年第3期11卷 649-660页

作者： Zhihong Liu Qinglong Jin Yuexin Zhang guozhong gong Guicheng Wu Lvfeng Yao Xiaofeng Wen Zhiliang Gao Yan Huang Daokun Yang Enqiang Chen Qing Mao Shide Lin Jia Shang Huanyu gong Lihua Zhong Huafa Yin Fengmei Wang Peng Hu Qiong Wu Chao Pan Wen Jia Chuan Li Chang’an Sun Junqi Niu Jinlin Hou TMF Study Group Department of Infectious Diseases and Hepatology Unit Institutes of Liver Diseases Research of Guangdong ProvinceNan-fang HospitalSouthern Medical UniversityGuangzhouGuangdongChina The First Hospital of Jilin University Chang-chunJilinChina The First Affiliated Hospital of Xinjiang Medical University UrumqiXinjiangChina The Second Xiangya Hospital of Central South University ChangshaHunanChina Chongqing University Three Gorges Hospital ChongqingChina Mengchao Hepatobiliary Hospital of Fujian Medical University FuzhouFujianChina Liuzhou People’s Hospital LiuzhouGuangxiChina The Third Affiliated Hospital of Zhongshan University GuangzhouGuangdongChina Xiangya Hospital of Central South University ChangshaHunanChina The First Affiliated Hospital of Xinxiang Medical University XinxiangHenanChina West China Hospital of Sichuan University ChengduSichuanChina The Southwest Hospi-tal of AMU ChongqingChina Affiliated Hospital of Zunyi Medical University ZunyiGuizhouChina Henan Provincial People’s Hospital ZhengzhouHenanChina The Third Xiangya Hospital of Central South University ChangshaHunanChina The Fourth Affiliated Hospital of Harbin Medical University HarbinHeilongjiangChina The First Affiliated Hospi-tal of Anhui Medical University HefeiAnhuiChina Tianjin Third Central Hospital TianjinChina The Second Affiliated Hospital of Chongqing Medical University ChongqingChina Jiangsu Hansoh Pharmaceutical Group Co. LtdLianyungangJiangsuChina Members listed in the Supplementary File 1

Background and Aims:Tenofovir amibufenamide(TMF)is a novel phosphoramidated prodrug of tenofovir with nonin-ferior efficacy and better bone and renal safety to tenofovir disoproxil fumarate(TDF)in 48 weeks of ***,we update 96-week comparison ***:Patients with chronic hepatitis B were assigned(2:1)to receive either 25 mg TMF or 300 mg TDF with matching placebo for 96 *** virological suppression was defined as HBV DNA levels<20 IU/mL at week *** was evaluated thoroughly with focusing on bone,renal,and metabolic ***:Virological suppression rates at week 96 were similar between TMF and TDF group in both HBeAg-positive and HBeAg-negative *** efficacy was maintained in the pooled population,while it was first achieved in patients with HBV DNA≥7 or 8 log10 IU/mL at ***-indexed estimated glomerular filtration rate for renal safety assessment was adopted,while a smaller decline of which was seen in the TMF group than in the TDF group(p=0.01).For bone mineral density,patients receiv-ing TMF displayed significantly lower reduction levels in the densities of spine,hip,and femur neck at week 96 than those receiving *** addition,the lipid parameters were stable after week 48 in all groups while weight change still showed the opposite ***:TMF maintained similar efficacy at week 96 compared with TDF with continued superior bone and renal safety profiles(NCT03903796).

关键词： Hepatitis B Liver function tests Viral hepatitis Liver Osteoporosis

药物性肝衰竭预后影响因素分析及其logistic回归模型构建

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中南大学学报（医学版） 2018年第12期43卷 1337-1344页

作者：周杰斌李倩龚国忠龚环宇侯周华中南大学湘雅医院感染病科病毒性肝炎湖南省重点实验室长沙410008 中南大学湘雅二医院感染病科长沙410011 中南大学湘雅三医院感染病科长沙410013

目的:研究药物性肝衰竭(drug-induced liver failure,DILF)患者的预后影响因素,并构建其logistic回归模型(logistic regression model,LRM)。方法:回顾性分析2009年1月至2018年1月在中南大学湘雅医院、湘雅二医院及湘雅三医院感染病科... 详细信息

目的:研究药物性肝衰竭(drug-induced liver failure,DILF)患者的预后影响因素,并构建其logistic回归模型(logistic regression model,LRM)。方法:回顾性分析2009年1月至2018年1月在中南大学湘雅医院、湘雅二医院及湘雅三医院感染病科收治的183例DILF患者的临床资料,根据其预后分为好转组(n=67)及无效组(n=116)。使用单因素分析对年龄,Tbil,SCr,PT及并发症等可能的预后影响因素进行初筛,基于单因素分析结果,进一步使用多因素分析筛选出独立的预后因素并构建LRM模型。将LRM模型与终末期肝病(model for end-stage liver disease,MELD)模型进行比较,采用受试者工作曲线(receiver operating characteristic curve,ROC)评估LRM模型和MELD模型的预测价值,比较两模型间ROC曲线下面积(area under the ROC curve,AUC)及总正确率等参数的优劣,并使用独立样本进行验证。结果:单因素分析提示:年龄,临床分型,肝性脑病,肝肾综合征,WBC计数,天门冬氨酸转氨酶/谷丙氨酸转氨酶(aspartic acid transaminase/glutarine transaminase,AST/ALT)比值,Tbil,SCr,PT和甲胎蛋白(alpha-fetoprotein,AFP)等指标在两组间的差异均有统计学意义(均P<0.05)。多因素分析提示:AFP,PT,AST/ALT比值,肝性脑病和肝肾综合征为DILF患者独立的预后影响因素,可用于构建LRM模型。LRM模型和MELD模型的AUC分别为0.917(95%CI:0.876～0.959)和0.709(95%CI:0.633～0.786),总正确率分别为86.7%和68.3%,差异有统计学意义(P<0.05)。结论:AFP,PT,AST/ALT比值,肝性脑病和肝肾综合征为DILF患者独立的预后影响因素;LRM模型能较准确地预测DILF患者的短期预后,其应用价值优于MELD模型。

关键词：药物肝功能衰竭多因素分析 logistic回归模型

Five-year Treatment with Tenofovir Alafenamide Achieves High Rates of Viral Suppression,Alanine Aminotransferase Normalization,and Favorable Bone and Renal Safety in Chinese Chronic Hepatitis B Patients

在线全文

学校读者我要写书评

暂无评论

Journal of Clinical and Translational Hepatology 2024年第5期12卷 469-480页

作者： Jinlin Hou Qin Ning Zhongping Duan Yu Chen Qing Xie Lunli Zhang Shanming Wu Hong Tang Jun Li Feng Lin Yongfeng Yang guozhong gong Yanwen Luo Shelley Xie Hongyuan Wang Roberto Mateo Tahmineh Yazdi Frida Abramov Leland JYee John Flaherty Chengwei Chen Yan Huang Mingxiang Zhang Jidong Jia Nanfang Hospital Southern Medical UniversityGuangzhouGuangdongChina Tongji Hospital Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubeiChina Beijing YouAn Hospital Capital Medical UniversityBeijingChina Shanghai Ruijin Hospital Shanghai Jiao Tong University School of MedicineShanghaiChina The First Affiliated Hospital of Nanchang University NanchangJiangxiChina Shanghai Public Health Clinical Center ShanghaiChina West China Hospital Sichuan UniversityChengduSichuanChina The First Affiliated Hospital of Nanjing Medical University NanjingJiangsuChina Hainan General Hospital HaikouHainanChina The Second Hospital of Nanjing Affiliated to Nanjing University of Chinese MedicineNanjingJiangsuChina The Second Xiangya Hospital Central South UniversityChangshaHunanChina Gilead Sciences ShanghaiChina Gilead Sciences Foster CityCAUSA The People’s Liberation Army No.85 Hospital ShanghaiChina Xiangya Hospital Central South UniversityChangshaHunanChina The Sixth People’s Hospital of Shenyang ShenyangLiaoningChina Beijing Friendship Hospital Capital Medical UniversityBeijingChina

Background and Aims:After 3-years(144 week)of double-blind treatment in Chinese chronic hepatitis B patients in two ongoing phase 3 studies,tenofovir alafenamide(TAF)showed similar efficacy to tenofovir disoproxil fumarate(TDF),with improved renal and bone *** this study,we aimed to report the 5-year results from 2 years into the open-label TAF treatment ***:All participants completing the 144-week double-blind treatment were eligible to receive open-label TAF 25 mg once daily up to week *** analysis of viral suppression(hepatitis B virus DNA<29 IU/mL),alanine aminotransferase normalization,serological responses,and safety outcomes at year 5(week 240)was ***:The openlabel phase included 93%(311/334)of the enrolled participants,which included 212 who switched from double-blind TAF to open-label TAF(TAF-TAF)and 99 who switched from double-blind TDF to open-label TAF(TDF-TAF).Baseline characteristics were *** 240 viral suppression rates were similar between groups[93.4%vs.93.9%;difference:-1.5%,(95%CI:-6.4 to-3.5),p=0.857].Alanine aminotransferase normalization and serological response rates were higher in the TAF-TAF group than in the TDF-TAF *** frequencies of adverse events and laboratory abnormalities were low and similar between *** groups had similar small numerical declines from baseline in estimated glomerular filtration rate at year 5(week 240,-2.85 mL/min vs.-3.29 mL/min,p=0.910).The greater declines in renal and bone parameters in the TDF-TAF group through week 144 improved after switching to ***:The 5-year TAF treatment efficacy was high and similar to that of 3-year TDF followed by 2-year TAF in Chinese chronic hepatitis B *** effects on bone and renal parameters were sustained with TAF treatment alone and were observed following the switch from TDF to TAF.

关键词： Chronic hepatitis B Antiviral therapy Bone safety Renal safety Tenofovir alafenamide Tenofovir disoproxil fumarate Chinese

3-year Treatment of Tenofovir Alafenamide *** Disoproxil Fumarate for Chronic HBV Infection in China

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Clinical and Translational Hepatology 2021年第3期9卷 324-334页

作者： Jinlin Hou Qin Ning Zhongping Duan You Chen Qing Xie Fu-Sheng Wang Lunli Zhang Shanming Wu Hong Tang Jun Li Feng Lin Yongfeng Yang guozhong gong John FFlaherty Anuj Gaggar Shuyuan Mo Cong Cheng Gregory Camus Chengwei Chen Yan Huang Jidong Jia Mingxiang Zhang GS-US-320-0110 and GS-US-320-0108 China Investigators Nanfang Hospital of Southern Medical University GuangzhouGuangdongChina Tongji Hospital Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubeiChina Beijing YouAn Hospital Capital Medical UniversityBeijingChina Shanghai Ruijin Hospital Shanghai Jiao Tong University School of MedicineShanghaiChina Beijing 302 Hospital BeijingChina The First Affiliated Hospital of Nanchang University NanchangJiangxiChina Shanghai Public Health Clinical Center ShanghaiChina West China Hospital Sichuan UniversityChengduSichuanChina The First Affiliated Hospital with Nanjing Medical University NanjingJiangsuChina Hainan General Hospital HaikouHainanChina Nanjing No.2 Hospital NanjingJiangsuChina The 2nd Xiangya Hospital Central South UniversityChangshaHunanChina Gilead Sciences Foster CityCAUSA Liver Disease Center of Naval 905 Hospital ShanghaiChina Xiangya Hospital Central South UniversityChangshaHunanChina Beijing Friendship Hospital Capital UniversityBeijingChina The Sixth People’s Hospital of Shenyang ShenyangLiaoningChina 不详

Background and Aims:Tenofovir alafenamide(TAF)has similar efficacy to tenofovir disoproxil fumarate(TDF)but with improved renal and bone safety in chronic hepatitis B patients studied outside of *** report 3-year results from two phase 3 studies with TAF in China(***:NCT02836249 and NCT02836236).Methods:Chinese hepatitis B e antigen(HBeAg)-positive and-negative chronic hepatitis B patients with viremia and elevated alanine aminotransferase were randomized 2:1 to TAF or TDF treatment groups and treated in a double-blind fashion for 144 weeks(3 years).Efficacy responses were assessed by individual study while safety was assessed by a pooled ***:Of the 334 patients(180 HBeAg-positive and 154 HBeAg-negative)randomized and treated,baseline characteristics were similar between *** overall mean age was 38 years and 73%were *** mean HBV DNA was 6.4 log10 IU/*** median alanine aminotransferase was 88 U/L,and 37%had a history of antiviral *** week 144,the proportion with HBV DNA<29 IU/mL was similar among the two groups,with TAF at 83%*** at 79%,and TAF at 93%*** at 92%for the HBeAg-positive and-negative patients,*** each study,higher proportions of TAF than TDF patients showed normalized alanine aminotransferase(via the American Association for the Study of Liver Diseases and the China criteria)and showed loss of HBsAg;meanwhile,the HBeAg seroconversion rates were *** was well-tolerated among the TAF patients,who showed a smaller median decline in creatinine clearance(−0.4 vs.−3.2 mL/min;p=0.014)and less percentage change in bone mineral density *** at hip(−0.95%vs.−1.93%)and spine(+0.35%vs.−1.40%).Conclusions:In chronic hepatitis B patients from China,TAF treatment provided efficacy similar to TDF but with better renal and bone safety at 3 years.

关键词： Chronic hepatitis B virus Antiviral therapy Bone safety Renal safety

HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog:New Switch Study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Clinical and Translational Hepatology 2018年第1期6卷 25-34页

作者： Peng Hu Jia Shang Wenhong Zhang guozhong gong Yongguo Li Xinyue Chen Jianning Jiang Qing Xie Xiaoguang Dou Yongtao Sun Yufang Li Yingxia Liu Guozhen Liu Dewen Mao Xiaoling Chi Hong Tang Xiaoou Li Yao Xie Xiaoping Chen Jiaji Jiang Ping Zhao Jinlin Hou Zhiliang Gao Huimin Fan Jiguang Ding Dazhi Zhang Hong Ren Department of Infectious Diseases The Second Affiliated Hospital of Chongqing Medical UniversityChongqingChina Department of Infectious Diseases Henan Provincial People's HospitalZhengzhouChina Department of Infectious Diseases Huashan HospitalFudan UniversityShanghaiChina Department of Infectious Diseases The Second Xiangya Hospital of Central South UniversityChangshaChina Department of Infectious Diseases The First Affiliated Hospital of Harbin Medical UniversityHarbinChina International Medical Department Beijing YouAn HospitalCapital Medical UniversityBeijingChina Department of Infectious Diseases The First Affiliated Hospital of Guangxi Medical UniversityNanningChina Department of Infectious Diseases Ruijin HospitalShanghai Jiaotong University School of MedicineShanghaiChina Department of Infectious Diseases Shengjing Hospital of China Medical UniversityShenyangChina Department of Infectious Diseases Tangdu HospitalFourth Military Medical UniversityXi'anChina Department of Infectious Diseases General Hospital of Ningxia Medical UniversityYinchuanChina Department of Infectious Diseases Shenzhen Third People's HospitalShenzhenChina Department of Infectious Diseases Xiangya Hospital Central South UniversityChangshaChina Liver Disease Department The First Affiliated Hospital of Guangxi University of Chinese MedicineNanningChina Liver Disease Department Guangdong Hospital of Traditional Chinese MedicineGuangzhouChina Center of Infectious Diseases West China HospitalSichuan UniversityChengduChina Liver Disease Department The Sixth People's Hospital of HangzhouZhejiangChina Liver Disease Department Beijing Ditan HospitalCapital Medical UniversityBeijingChina Department of Infectious Diseases Guangdong General HospitalGuangzhouChina Center of Liver Diseases The First Affiliated Hospital of Fujian Medical UniversityFuzhouChina International Center for Liver Disease Treatment 302 Hospital of PLABeijingChina Department of Infectious Diseases and Hepatology Unit Nanfang Ho

Background and Aims:Hepatitis B surface antigen(HBsAg)loss is seldom achieved with nucleos(t)ide analog(NA)therapy in chronic hepatitis B patients but may be enhanced by switching to finite pegylated-interferon(Peg-IFN)*** assessed HBsAg loss with 48-and 96-week Peg-IFN alfa-2a in chronic hepatitis B patients with partial response to a previous ***:Hepatitis B e antigen(HBeAg)-positive patients who achieved HBeAg loss and hepatitis B virus DNA<200 IU/mL with previous adefovir,lamivudine or entecavir treatment were randomized 1:1 to receive Peg-IFN alfa-2a for 48(n=153)or 96 weeks(n=150).The primary endpoint of this study was HBsAg loss at end of *** *** identifier is ***:At the end of 48 and 96 weeks'treatment,14.4%(22/153)and 20.7%(31/150)of patients,respectively,who switched from NA to Peg-IFN alfa-2a cleared *** were similar irrespective of prior NA or baseline HBeAg *** those who cleared HBsAg by the end of 48 and 96 weeks'treatment,77.8%(14/18)and 71.4%(20/28),respectively,sustained HBsAg loss for a further 48 *** HBsAg<1500 IU/mL and week 24 HBsAg<200 IU/mL were associated with the highest rates of HBsAg loss at the end of both 48-and 96-week treatment(51.4%and 58.7%,respectively).Importantly,extending treatment from 48 to 96 weeks enabled 48.3%(14/29)more patients to achieve HBsAg ***:Patients on long-term NA who are unlikely to meet therapeutic goals can achieve high rates of HBsAg loss by switching to Peg-IFN *** loss rates may be improved for some patients by extending treatment from 48 to 96 weeks,although the differences in our study cohort were not statistically *** and on-treatment HBsAg may predict HBsAg loss with Peg-IFN alfa-2a.

关键词： Antiviral therapy Peg-interferon Nucleos(t)ide treated Chronic hepatitis B

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

浅谈网络应用与多媒体教学

天津科技 2016年第6期43卷 78-80页

作者：巩国忠天津现代职业技术学院天津300222

网络的特点是集成化、开放化、多元化。多媒体是集图、文、声为一体的传播技术。在当今高速发展的网络时代,教学不论从教学方式、教学质量、培养模式还是教学中的文化理念都应该有一个从量到质的飞跃,应建立在网络应用之上。尤其是在教... 详细信息

网络的特点是集成化、开放化、多元化。多媒体是集图、文、声为一体的传播技术。在当今高速发展的网络时代,教学不论从教学方式、教学质量、培养模式还是教学中的文化理念都应该有一个从量到质的飞跃,应建立在网络应用之上。尤其是在教学中建立网络应用的概念,使教育者和被教育者都能步入网络时代的大潮中。分析了网络应用与多媒体教学结合的意义与路径,指出利用网络实现多媒体教学具有深远意义。

关键词：网络多媒体数字化信息时代资源共享

Efficacy and Safety of All-oral,12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naive Noncirrhotic HCV Genotype 1 Patients:Results from a Phase 2/3 Clinical Trial in China

在线全文

学校读者我要写书评

暂无评论

Journal of Clinical and Translational Hepatology 2019年第3期7卷 213-220页

作者： Xiaoyuan Xu Bo Feng Yujuan Guan Sujun Zheng Jifang Sheng Xingxiang Yang Yuanji Ma Yan Huang Yi Kang Xiaofeng Wen Jun Li Youwen Tan Qing He Qing Xie Maorong Wang Ping An guozhong gong Huimin Liu Qin Ning Rui Hua Bo Ning Wen Xie Jiming Zhang Wenxiang Huang Yongfeng Yang Minghua Lin Yingren Zhao Yanhong Yu Jidong Jia Dongliang Yang Liang Chen Yinong Ye Yuemin Nan Zuojiong gong Quan Zhang Peng Hu Fusheng Wang Yongguo Li Dongliang Li Zhansheng Jia Jinlin Hou Chengwei Chen Jinzi JWu Lai Wei Peking University First Hospital BeijingChina Peking University People's Hospital BeijingChina Guangzhou Eighth People's Hospital GuangzhouChina Beijing YouAn Hospital Capital Medical UniversityBeijingChina The First Affiliated Hospital of Medical School of Zhejiang University HangzhouChina Sichuan Provincial People's Hospital ChengduChina West China Hospital Sichuan UniversityChengduChina Xiangya Hospital Central South UniversityChangshaChina Henan Provincial People's Hospital ZhengzhouChina Liuzhou People's Hospital LiuzhouChina Jiangsu Province Hospital NanjingChina Zhenjiang No.3 People's Hospital ZhenjiangChina The Third People's Hospital of Shenzhen ShenzhenChina Ruijin Hospital Shanghai Jiaotong University School of MedicineShanghaiChina People's Liberation Army Bayi Hospital NanjingChina Shenyang Sixth People's Hospital ShenyangChina The 2nd Xiangya Hospital of Central South University ChangshaChina Xixi Hospital of Hangzhou HangzhouChina Tongji Medical College of Huazhong University of Science&Technology WuhanChina The First Hospital of Jilin University ChangchunChina Baoji Center Hospital BaojiChina Beijing Ditan Hospital BeijingChina Huashan Hospital Affiliated to Fudan University ShanghaiChina Chongqing Medical University No.1 Affiliated Hospital ChongqingChina The Second Hospital of Nanjing NanjingChina Fujian Fuzhou Municipal Infectious Disease Hospital FuzhouChina No.1 Affiliated Hospital of Xi'an Jiaotong University Xi'anChina The First Affiliated Hospital of Guangxi Medical University NanningChina Beijing Friendship Hospital Capital Medical UniversityBeijingChina Wuhan Union Hospital WuhanChina Shanghai Public Health Clinical Center ShanghaiChina Foshan No.1 People's Hospital FoshanChina The Third Hospital of Hebei Medical University ShijiazhuangChina Wuhan University Renmin Hospital WuhanChina The Affiliated Hospital of Guizhou Medical University GuiyangChina The Second Affiliated Hospital of Chongqing Medical University ChongqingChina PLA 302 Hospital Be

Background and Aims:Ravidasvir(RDV)is a new generation pangenotypic hepatitis C virus(HCV)NS5A inhibitor,with high barrier to baseline resistance-associated *** is the first phase 2/3 study conducted in China's Mainland confirming the efficacy and safety of RDV+ritonavir-boosted danoprevir+ribavirin for 12 weeks in treatment-naive noncirrhotic patients with genotype 1 infection in a large ***:In this multicenter,randomized,doubleblinded,placebo-controlled phase 2/3 trial(NCT03362814),we enrolled 424 treatment-nafve,noncirrhotic adult HCV genotype 1 *** patients were randomized at 3∶1 ratio to receive a combination of RDV 200mg once daily plus ritonavir-boosted danoprevir 100mg/100mg twice daily and oral ribavirin 1000/1200mg/day(body weight<75/≥75 kg)(n=318)or placebo(n=106)for 12 *** primary end-point was the rate of sustained virologic response 12 weeks after the end of treatment,and the safety was evaluated and compared between treatment and placebo ***:The overall rate of sustained virological response at 12 weeks after treatment is 99%(306/309,95%,CI:97%-100%)under per protocol set *** patients harboring baseline NS5A resistance-associated species in the treatment group(76/76,per protocol set)achieved sustained virological response at 12 weeks after *** treatment-related serious adverse events were *** abnormalities showed mild or moderate severity(grade 1 and grade 2)in liver function ***:In treatment-na(i)ve,noncirrhotic HCV Chinese patients infected with HCV genotype 1,all-oral regimen of RDV+ritonavir-boosted danoprevir+ribavirin for 12 weeks was highly efficacious,safe,and well tolerated.

关键词： Ravidasvir Danoprevir HCV SVR Treatment-naive Noncirrhotic GT1

重组细胞因子基因衍生蛋白注射液(乐复能)治疗HBeAg阳性慢性乙型肝炎的疗效和安全性

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中华临床感染病杂志 2020年第4期13卷 276-281页

作者：汪玲龚国忠孙克伟龚环宇王文龙张涛张浩晔谭德明中南大学湘雅医院感染科长沙410005 中南大学湘雅二医院感染科长沙410000 湖南中医药大学第一附属医院感染科长沙410007 中南大学湘雅三医院感染科长沙410006

目的观察重组细胞因子基因衍生蛋白注射液(乐复能)治疗HBeAg阳性慢性乙型肝炎(CHB)患者的有效性及安全性。方法前瞻性收集2010年6月1日至2011年9月6日中南大学湘雅医院、中南大学湘雅二医院、中南大学湘雅三医院和湖南中医药大学第一附... 详细信息

目的观察重组细胞因子基因衍生蛋白注射液(乐复能)治疗HBeAg阳性慢性乙型肝炎(CHB)患者的有效性及安全性。方法前瞻性收集2010年6月1日至2011年9月6日中南大学湘雅医院、中南大学湘雅二医院、中南大学湘雅三医院和湖南中医药大学第一附属医院收治的HBeAg阳性CHB患者360例。按照1∶1比例随机分为实验组(n=180)和对照组(n=180),实验组患者予乐复能,对照组患者予人干扰素α-2b,双盲治疗12周后进入开放标签阶段,在患者自愿基础上,实验组患者继续使用乐复能,对照组患者转向使用乐复能,治疗12周后停药随访12周和52周。治疗和随访阶段检查血常规、肝功能、HBV DNA等指标,分析乐复能治疗HBeAg阳性CHB患者的有效性。采用SAS 9.1.3对数据进行统计分析。结果双盲治疗12周后,实验组和对照组的HBeAg血清转阴率分别为27.11%和16.17%,差异具有统计学意义(χ^2=5.98,P0.05)。进入开放标签阶段和随访阶段,实验组的HBeAg血清转阴率、HBeAg血清学转换率、HBV DNA转阴率及ALT复常率均继续升高。不良反应事件监测中,实验组患者的头痛、乏力发生率均低于对照组(P0.05)。结论乐复能可更好地促进CHB患者HBeAg转阴及血清学转换。乐复能治疗HBeAg阳性的CHB患者安全、有效。

关键词：肝炎,乙型,慢性重组细胞因子基因衍生蛋白注射液乐复能干扰素α-2b 治疗结果